Clinical trials
Completed Neuroectodermal Tumors, Primitive, Peripheral trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 8 |
| 2002 | 6 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 6 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 8 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 85 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 28 |
| Children's Oncology Group | 16 |
| Memorial Sloan Kettering Cancer Center | 9 |
| National Institutes of Health Clinical Center (CC) | 5 |
| City of Hope Medical Center | 4 |
| Fred Hutchinson Cancer Center | 2 |
| St. Jude Children's Research Hospital | 2 |
| Amgen | 1 |
| Case Comprehensive Cancer Center | 1 |
| Columbia University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuroectodermal Tumors, Primitive, Peripheral | 85 |
| Sarcoma | 58 |
| Osteosarcoma | 47 |
| Neuroblastoma | 37 |
| Medulloblastoma | 26 |
| Central Nervous System Neoplasms | 23 |
| Wilms Tumor | 23 |
| Astrocytoma | 20 |
| Rhabdomyosarcoma | 19 |
| Testicular Neoplasms | 18 |
Trials
Showing 1 to 25 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.